China has moved brain-computer interfaces from experimental research closer to the commercial market, intensifying a technology race with Elon Musk’s Neuralink and other companies developing devices that connect the human brain to computers.
The development accelerated in March 2026 when China’s National Medical Products Administration (NMPA) approved an implantable brain-computer interface developed by Shanghai-based Neuracle Technology for patients with quadriplegia caused by cervical spinal cord injuries.
The approval was described by Chinese state media as the world’s first market approval for an invasive BCI medical device, marking a significant shift from laboratory research and clinical experimentation towards actual medical deployment.
The device, known as NEO, is designed to decode brain signals and use them to help patients control a pneumatic glove capable of assisting hand-grasping movements.
That milestone has become part of a much larger push by Beijing to develop brain-computer interfaces as a strategic technology, putting China increasingly alongside Neuralink and other international BCI developers in a rapidly evolving field.
China’s Brain-Chip Push Is Bigger Than One Device
The commercial approval of Neuracle’s system is only one part of China’s expanding BCI programme.
China designated brain-computer interfaces as a future industry in its 2026 government work report and included the sector in the country’s 15th Five-Year Plan for 2026–2030.
Government targets call for major breakthroughs in BCI technology, industrial development and standards by 2027, with the longer-term ambition of significantly strengthening China’s global position in the sector by 2030.
Chinese regulators have also been working to establish clearer rules for the emerging industry. In June, the NMPA issued guidance covering the classification and generic naming of BCI medical devices, including invasive and implantable systems.
The policy push means China is attempting to build not just individual brain implants but an ecosystem around research, manufacturing, clinical trials, regulation and eventual commercial adoption.
What China’s Approved Brain Implant Actually Does
It is important to separate current medical applications from the more futuristic claims sometimes associated with brain chips.
Neuracle’s approved system is aimed at people with severe motor impairment. The implant records and decodes brain signals, allowing patients to operate a pneumatic glove designed to assist grasping functions.
According to Xinhua, the system uses an epidural implantation approach and was developed for adults aged 18 to 60 with quadriplegia resulting from cervical spinal cord injuries. The company reported that the device had already been used in 36 clinical procedures, including feasibility work and multicentre clinical trials, before market approval.
That is very different from the idea of a general-purpose chip capable of reading memories, connecting directly to artificial intelligence or giving healthy people enhanced cognitive abilities.
For now, the most credible applications are medical: helping people who have lost motor functions communicate with computers, control assistive equipment or regain some degree of physical independence.
China Is Also Testing Other Brain-Computer Systems
Neuracle is not operating alone.
The Chinese Institute for Brain Research in Beijing and NeuCyber NeuroTech have been developing Beinao-1, a semi-invasive BCI system in which an implant is placed inside the head while electrodes sit on the outer surface of the dura mater rather than penetrating brain tissue.
Clinical trials of Beinao-1 began in March, with patient enrolment under way. Another system, Beinao-2, is being developed as a more advanced invasive BCI and has entered large-animal testing.
Another Chinese company, BCIFlex, unveiled a 1,000-channel invasive BCI system in March. Its flexible electrode design is intended to reduce problems caused by movement between brain tissue and the skull, one of the technical challenges facing long-term implanted BCIs.
China is also expanding non-invasive applications. In July, authorities announced plans to promote smart rehabilitation devices incorporating non-invasive BCI technology during the 2026–2030 period, particularly for people with disabilities.
Then There Is Elon Musk’s Neuralink
The Chinese push is unfolding as Neuralink continues its own human trials.
Neuralink’s technology uses an implant containing neural-recording electrodes and is designed to translate brain activity into commands for external devices.
The company says participants in its clinical trials have used Neuralink devices to control computers and robotic arms with their thoughts. Neuralink reported in January 2026 that 21 participants had received its implant as part of its clinical programme.
University College London Hospitals also reported in January that seven patients were participating in the GB-PRIME study involving Neuralink’s technology in Britain. The study is aimed at improving independence for people living with paralysis.
Neuralink’s own materials describe its current technology as an investigational medical device rather than a product available for general sale. Its initial clinical work focuses on people with severe paralysis and the ability to control external devices through neural signals.
China and Neuralink Are Not Yet Doing Exactly the Same Thing
The growing rivalry should not be interpreted as meaning China has simply surpassed Neuralink across every measure.
The two ecosystems are developing different devices, surgical approaches and clinical programmes, making direct comparisons difficult.
Neuralink has accumulated human-trial experience with its intracortical system, while China’s recent milestone is particularly significant because its NMPA approval moved an invasive BCI into the regulated commercial medical-device market.
Chinese researchers are simultaneously working on invasive, semi-invasive and non-invasive systems, suggesting that Beijing is pursuing multiple technological routes rather than betting everything on one architecture.
Recent reporting has nevertheless highlighted the growing U.S.-China competition over brain implants, with BCIs becoming another frontier in the broader race over biotechnology and advanced medical technology.
The Technology Still Has Major Problems to Solve
Despite the excitement surrounding brain chips, the technology remains far from the science-fiction scenarios sometimes associated with it.
Implanted BCIs must reliably capture extremely small neural signals while remaining safe inside or around the brain for long periods. Researchers are still working on electrode durability, signal degradation, power systems, surgical risks and the ability of devices to maintain performance over time.
There are also major questions about privacy and control.
If a device can decode increasingly detailed information from brain activity, questions about who owns neural data, how it can be stored, whether it can be shared and how much control users retain over systems interpreting their brain signals will become increasingly important.
Those questions become even more complicated as artificial intelligence is incorporated into BCI systems. Recent research has highlighted the need to evaluate AI-assisted BCIs not only for technical performance but also for user agency, intent and safety.
Why China Wants to Move Quickly
China’s push is consistent with a wider strategy of identifying emerging technologies that could become major industries.
The country’s 2026 policy framework treats BCI as part of a broader group of future technologies alongside areas such as robotics and other advanced industries.
That approach gives Chinese developers access to a combination of research institutions, hospitals, regulators, manufacturing capacity and government-backed industrial policy.
It also creates an environment in which successful laboratory technologies can potentially move into clinical trials and commercialisation faster.
China’s broader technological ambitions have increasingly extended into artificial intelligence, robotics, digital infrastructure and advanced medical technology. The Bureau Journal has previously examined how artificial intelligence is changing everyday life and the implications of the technology for work and society.
What Brain Chips Could Mean for Patients
The most immediate promise of BCIs is not immortality or human-machine fusion.
It is restoring abilities that neurological injury or disease has taken away.
A person who cannot move their hands could potentially control a robotic arm. Someone who has lost the ability to communicate could eventually use neural signals to interact with a computer. Rehabilitation systems could use brain activity to help patients relearn movements.
Chinese researchers are already pursuing these applications. In July, Xinhua reported a demonstration in which two people with spinal cord injuries used a China-developed implantable BCI to play Chinese chess, with one participant controlling a virtual board through brain signals while another operated a robotic glove to move physical pieces.
China has also begun clinical work on visual BCI technology. In May 2026, a woman who had been almost completely blind for nearly two decades became the first person in China to receive a high-resolution retina-based BCI implant in a clinical trial, according to Xinhua.
The Next Battle May Be Commercial, Not Just Scientific
The most important development in China’s BCI programme may ultimately be the shift from invention to infrastructure.
Developing a prototype is one challenge. Building a reliable medical-device industry around it is another.
That requires regulatory pathways, manufacturing standards, hospitals capable of performing the procedures, trained surgeons, long-term patient monitoring, insurance or reimbursement mechanisms and evidence that the technology produces meaningful benefits.
China has already begun addressing several of those pieces.
In 2025, the country’s National Healthcare Security Administration issued a pricing guideline that recognised BCI as an independent category of neural-system care services, while 2026 has brought further regulatory and clinical developments.
The global BCI race is therefore moving into a new phase.
It is no longer simply about who can build a brain implant.
It is increasingly about who can make the technology safe, clinically useful, scalable and commercially viable.
China’s Brain-Chip Race Is Just Beginning
China’s first market approval for an invasive BCI does not mean brain chips have suddenly become mainstream consumer technology.
It does, however, mark an important change in the industry’s trajectory.
A technology once confined largely to laboratories and experimental trials is now entering a more structured medical and commercial ecosystem in China, while Neuralink and other companies continue their own clinical programmes.
For patients living with paralysis, stroke-related disability, neurological disease and other conditions, that competition could eventually accelerate the development of technologies capable of restoring lost functions.
For governments and technology companies, it represents something larger: a race to determine who will build the infrastructure and intellectual property behind one of the most consequential interfaces between humans and machines.
And unlike some of the more futuristic promises surrounding brain chips, that race is already happening.
The Bureau Journal will continue to follow developments in artificial intelligence, robotics, medical technology and the emerging technologies reshaping the global economy.
Get breaking news and latest updates directly on WhatsApp
